Le Lézard
Classified in: Business
Subject: STR

Canadian Investment Regulatory Organization Trade Resumption - METL


VANCOUVER, BC, Feb. 21, 2024 /CNW/ - Trading resumes in:

Company: Metalite Resources Inc.

CSE Symbol: METL

All Issues: Yes

Resumption (ET): 11:15 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) ? Halts/Resumptions


These press releases may also interest you

at 10:01
Cognizant today announced a five-year strategic partnership with Telstra as part of the Australian telecommunications and technology company's strategy for growth. Cognizant will introduce new ways of working to accelerate Telstra's software...

at 10:00
Pomerantz LLP announces that a class action lawsuit has been filed against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ("Nextdoor" or the "Company") . Such investors are advised to contact Danielle Peyton at...

at 10:00
Pomerantz LLP announces that a class action lawsuit has been filed against Lyft, Inc. ("Lyft" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980....

at 10:00
Pomerantz LLP announces that a class action lawsuit has been filed against The Children's Place, Inc. ("The Children's Place" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or...

at 09:45
NEW YORK, April 28, 2024 Pomerantz LLP is investigating claims on behalf of investors of Harbor Diversified, Inc. ("Harbor" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 09:45
Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....



News published on and distributed by: